CTXR and CTOR Related Headlines
Go Back- Citius Oncology reports positive phase 1 data for LYMPHIR cancer treatment
- Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
- Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
- Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
- Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
- Citius Oncology signs exclusive European distribution deal with Uniphar
- Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
- Citius Pharmaceuticals launches cancer drug LYMPHIR following FDA approval
- Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
- Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
- Citius Oncology closes $18 million stock offering at $1.09 per share
- Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
- Citius Oncology raises $18 million in stock offering for LYMPHIR launch
- Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
- Citius Oncology partners with Er-Kim for LYMPHIR distribution in Turkey, GCC
- Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
- Citius Oncology launches LYMPHIR cancer treatment nationwide
- Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
- Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
- Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
- Citius Pharmaceuticals closes $6 million direct offering
- Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
- Citius Pharmaceuticals raises $6 million in registered direct offering
- Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
- Citius Oncology signs distribution deal with McKesson for LYMPHIR launch
- Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
- Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
- Citius Oncology partners with EVERSANA for LYMPHIR drug launch
- Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
- Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe
- Citius Oncology closes $9 million equity offering
- Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
- Citius Oncology prices $9 million offering at $1.75 per share
- Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
- Citius Oncology deploys AI platform ahead of LYMPHIR launch
- Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
- Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
- Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
- Citius Oncology closes $9 million public offering
- Citius Oncology Announces Closing of $9.0 Million Public Offering
- Citius Oncology Announces Closing of $9.0 Million Public Offering
- Citius Oncology prices $9 million public offering at $1.32 per share
- Citius Oncology Announces Pricing of $9.0 Million Public Offering
- Citius Oncology signs distribution deal with Cencora for LYMPHIR
- Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
- Citius Pharmaceuticals regains Nasdaq compliance
- Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Citius Oncology (CTOR) Anticipates Commercial Launch of LYMPHIR in 2025
- Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
- Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
CTXR and CTOR Related Press Releases
Go Back- Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
- Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
- Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
- Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
- Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
- Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
- Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
- Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
- Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
- Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
- Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
- Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
- Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
- Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
- Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
- Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
- Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
- Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
- Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe
- Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
- Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
- Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
- Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
- Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
- Citius Oncology Announces Closing of $9.0 Million Public Offering
- Citius Oncology Announces Closing of $9.0 Million Public Offering
- Citius Oncology Announces Pricing of $9.0 Million Public Offering
- Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
- Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
- Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
CTXR and CTOR Related SEC Filings
Go Back- Form 8-K CITIUS ONCOLOGY, INC. For: Mar 04
- Form EFFECT CITIUS ONCOLOGY, INC.
- Form POS AM CITIUS ONCOLOGY, INC.
- Form SCHEDULE 13G/A CITIUS ONCOLOGY, INC. Filed by: ARMISTICE CAPITAL, LLC
- Form 8-K CITIUS ONCOLOGY, INC. For: Feb 13
- Form 10-Q CITIUS ONCOLOGY, INC. For: Dec 31
- Form DEF 14C CITIUS ONCOLOGY, INC. For: Jan 29
- Form PRE 14C CITIUS ONCOLOGY, INC. For: Jan 20
- Form EFFECT CITIUS ONCOLOGY, INC.
- Form S-3 CITIUS ONCOLOGY, INC.
- Form 8-K CITIUS ONCOLOGY, INC. For: Dec 23
- Form 10-K CITIUS ONCOLOGY, INC. For: Sep 30
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Mayersohn Joel David
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Bartushak Jaime
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Dutia Suren G
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Mazur Leonard L
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: HOLUBIAK MYRON Z
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Webb Carol
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Czuczman Myron
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Smith Robert Joseph
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Holuka Eugene Myron
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: MCGRATH DENNIS M
- Form SCHEDULE 13D/A CITIUS ONCOLOGY, INC. Filed by: Citius Pharmaceuticals, Inc.
- Form 8-K CITIUS ONCOLOGY, INC. For: Dec 08
- Form 424B5 CITIUS ONCOLOGY, INC.
- Form 8-K CITIUS ONCOLOGY, INC. For: Dec 01
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: MCGRATH DENNIS M
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: HOLUBIAK MYRON Z
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Dutia Suren G
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Mazur Leonard L
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Smith Robert Joseph
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Webb Carol
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Bartushak Jaime
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Holuka Eugene Myron
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Mayersohn Joel David
- Form 4/A CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Czuczman Myron
- Form SCHEDULE 13G CITIUS ONCOLOGY, INC. Filed by: ARMISTICE CAPITAL, LLC
- Form 8-K CITIUS ONCOLOGY, INC. For: Oct 27
- Form 8-K CITIUS ONCOLOGY, INC. For: Oct 23
- Form DEF 14A CITIUS ONCOLOGY, INC. For: Oct 27
- Form 4 CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: MCGRATH DENNIS M
- Form 4 CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Dutia Suren G
- Form 4 CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Bartushak Jaime
- Form 4 CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Holuka Eugene Myron
- Form 4 CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Mayersohn Joel David
- Form 4 CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Webb Carol
- Form 4 CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Czuczman Myron
- Form 4 CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Mazur Leonard L
- Form 4 CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: Smith Robert Joseph
- Form 4 CITIUS ONCOLOGY, INC. For: Sep 19 Filed by: HOLUBIAK MYRON Z
- Form S-8 CITIUS ONCOLOGY, INC.
- Form 8-K CITIUS ONCOLOGY, INC. For: Sep 19
- Form SCHEDULE 13D/A CITIUS ONCOLOGY, INC. Filed by: Citius Pharmaceuticals, Inc.
- Form 424B3 CITIUS ONCOLOGY, INC.
- Form 8-K CITIUS ONCOLOGY, INC. For: Sep 09
- Form 424B5 CITIUS ONCOLOGY, INC.
- Form EFFECT CITIUS ONCOLOGY, INC.
- Form S-3 CITIUS ONCOLOGY, INC.
- Form 8-K CITIUS ONCOLOGY, INC. For: Aug 18
- Form 424B3 CITIUS ONCOLOGY, INC.
- Form 8-K CITIUS ONCOLOGY, INC. For: Aug 12
- Form 10-Q CITIUS ONCOLOGY, INC. For: Jun 30
- Form 4 CITIUS ONCOLOGY, INC. For: Jul 28 Filed by: Mayersohn Joel David
- Form SCHEDULE 13D/A CITIUS ONCOLOGY, INC. Filed by: Citius Pharmaceuticals, Inc.
- Form 8-K CITIUS ONCOLOGY, INC. For: Jul 16
- Form EFFECT CITIUS ONCOLOGY, INC.
- Form 424B4 CITIUS ONCOLOGY, INC.
- Form S-1/A CITIUS ONCOLOGY, INC.
- Form S-1 CITIUS ONCOLOGY, INC.
- Form 8-K CITIUS ONCOLOGY, INC. For: Jun 26
- Form 8-K CITIUS ONCOLOGY, INC. For: Jun 17
